文献速递胸部肿瘤

在经一线含铂双药化疗失败的晚期鳞状细胞非小细胞肺癌患者中按VeriStrat良好与VeriStrat不良分层比较厄洛替尼与多西他赛的随机III期试验:欧洲胸科肿瘤平台(ETOP)EMPHASIS-lung试验

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
PubMed 文献 · J Thorac Oncol · 2016-12-23

EMPHASIS-lung是一项随机III期多中心试验,因入组缓慢和同期其他试验结果而提前终止,共随机80例晚期鳞状细胞NSCLC患者,72.5%为VeriStrat良好。最终分析未显示厄洛替尼与多西他赛按VeriStrat状态分层在PFS上存在差异效应;与PROSE试验鳞癌亚组47例的探索性合并分析中,治疗与VeriStrat状态的交互作用无统计学显著性(PFS交互p=0.24,OS交互p=0.45,按研究分层)。

要点

  • EMPHASIS-lung因入组缓慢和同期其他试验结果提前终止,共随机80例患者。
  • VeriStrat良好队列中多西他赛与厄洛替尼的中位PFS分别为4.1个月和1.6个月。
  • 最终分析未显示按VeriStrat状态分层厄洛替尼与多西他赛在PFS上的差异效应。

核心结论

  • EMPHASIS-lung最终分析未显示按VeriStrat状态分层厄洛替尼与多西他赛在PFS上的差异效应。
  • 在合并分析中,未观察到治疗与VeriStrat状态间有统计学显著的交互作用(PFS交互p=0.24,OS交互p=0.45,按研究分层)。

研究设计与样本

  • EMPHASIS-lung是一项随机III期多中心试验,探索二线厄洛替尼与多西他赛在VeriStrat良好与VeriStrat不良鳞状细胞NSCLC患者中对PFS的差异效应。
  • 共随机80例患者,其中72.5%归类为VeriStrat良好。
  • 患者特征在VeriStrat状态和治疗组间均衡。
  • 该试验因入组缓慢和其他试验结果而提前终止。
  • 分析包含与PROSE试验结果进行的探索性合并分析,纳入PROSE鳞状细胞亚组47例患者,贡献45例PFS事件和41例OS事件。

主要发现

  • VeriStrat良好队列中,多西他赛与厄洛替尼治疗的中位PFS分别为4.1个月和1.6个月。
  • VeriStrat不良队列中,多西他赛与厄洛替尼治疗的中位PFS分别为1.9个月和2.1个月。
  • VeriStrat良好队列中,多西他赛与厄洛替尼治疗的中位OS分别为7.8个月和8.4个月。
  • VeriStrat不良队列中,多西他赛与厄洛替尼治疗的中位OS分别为4.4个月和5.2个月。

局限性

  • 该试验因入组缓慢和其他试验结果而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial. METHODS: EMPHASIS-lung was a randomized phase III multicenter trial exploring the differential effect of second-line erlotinib versus docetaxel on progression-free survival (PFS) in VeriStrat good versus VeriStrat poor patients with squamous cell NSCLC. RESULTS: A total of 80 patients were randomized, with 72.5% categorized as VeriStrat good. Patient characteristics were balanced between VeriStrat status and treatment groups. The median PFS times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 4.1 and 1.6 months, respectively, versus 1.9 and 2.1 months, respectively, in the VeriStrat poor cohort. The median overall survival (OS) times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 7.8 and 8.4 months, respectively, and 4.4 and 5.2 months, respectively, in the VeriStrat poor cohort. An additional exploratory analysis was performed; in it, 47 patients from the squamous cell subgroup of PROSE were included in a combined analysis, contributing with 45 PFS and 41 OS events. CONCLUSIONS: The final analysis of EMPHASIS-lung did not show a differential effect on PFS for erlotinib versus docetaxel stratified by VeriStrat status. Similarly, in the combined analysis, no significant treatment by VeriStrat status interaction was observed (interaction p = 0.24 for PFS and 0.45 for OS, stratified by study).

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Stahel RA, Dafni U, et al. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol. 2016. PMID: 28017787. doi:10.1016/j.jtho.2016.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。